Table 3.
Relationship between morphological features, kinetics patterns of enhancement and biological parameters
| Biological Parameters | Morphological features | N° | Kinetic features | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Margin | Enhancement internal | Peak of maximum enhancement | % of maximum enhancement < 2' | Curve Type | |||||||||
| N°* | A | B | Hom | Het/Rim | < 2' | ≥ 2' | ≤ 150% | > 150% | I | II | III | ||
| Total cases | 64 | 68 | |||||||||||
| Estrogen receptors** | |||||||||||||
| Negative | 13 | 3 (23.1) | 10 (76.9) | 2 (15.4) | 11 (84.6) | 14 | 3 (21.4) | 11 (78.6) | 9 (64.3) | 5 (35.7) | - | 9 (64.3) | 5 (35.7) |
| Positive | 51 | 13 (25.5) | 38 (74.5) | 10 (19.6) | 41 (80.4) | 54 | 14 (25.9) | 40 (74.1) | 30 (55.6) | 24 (44.4) | 5 (9.2) | 15 (27.8) | 34 (63) |
| Progesterone receptors** | |||||||||||||
| Negative | 18 | 4 (22.2) | 14 (77.8) | 3 (16.7) | 15 (83.3) | 20 | 6 (30) | 14 (70) | 12 (60) | 8 (40) | - | 9 (45) | 11 (55) |
| Positive | 46 | 12 (26.1) | 34 (73.9) | 9 (19.6) | 37 (80.4) | 48 | 11 (22.9) | 37 (77.1) | 27 (56.3) | 21 (43.7) | 5 (10.4) | 15 (31.3) | 28 (58.3) |
| p53** | |||||||||||||
| Negative | 52 | 11 (21.2) | 41 (78.8) | 9 (17.3) | 43 (82.7) | 56 | 14 (25) | 42 (75) | 31 (55.4) | 25 (44.6) | 5 (8.9) | 19 (33.9) | 32 (57.2) |
| Positive | 12 | 5 (41.7) | 7 (58.3) | 3 (25) | 9 (75) | 12 | 3 (25) | 9 (75) | 8 (66.7) | 4 (33.3) | - | 5 (41.7) | 7 (58.3) |
| HER2** | |||||||||||||
| Negative | 38 | 10 (26.3) | 28 (73.7) | 8 (21.1) | 30 (78.9) | 41 | 9 (22) | 32 (78) | 23 (56.1) | 18 (43.9) | 5 (12.2) | 15 (36.6) | 21 (51.2) |
| Positive | 26 | 6 (23.1) | 20 (76.9) | 4 (15.4) | 22 (84.6) | 27 | 8 (29.6) | 19 (70.4) | 16 (59.3) | 11 (40.7) | - | 9 (33.3) | 18 (66.7) |
| Ki67** | 64 | 17.5 (3-85) |
20 (1-95) |
17.5 (5-85) |
20 (1-95) |
68 | 20 (3-95) |
15 (1-85) |
20 (1-85) |
15 (1-95) |
5 (5-45) |
15 (1-85) |
20 (3-95) |
| VEGFR-1# | 64 | 59.4 (0-216.1) |
54.8 (0-191) |
60.7 (0-216.1) |
54.2 (0-191) |
68 | 53.6 (0-216.1) |
54.7 (0-191) |
56.5 (0-216.1) |
49.6 (0-139.5) |
0 (0-103.4) |
50.2 (0-145.8) |
56.5 (0-216.1) |
| VEGFR-2# | 64 | 40.9 (0-126.8) |
37.7 (0-155.5) |
18.8 (0-155.5) |
39.7 (0-140.9) |
68 | 39.2 (0-122.1) |
34.1 (0-155.5) |
36.2 (0-133.6) |
32.8 (0-155.5) |
0 (0-56.2) |
34 (0-155.5) |
39.2 (0-140.9) |
* Four cases showed a non-nodular enhancement, so the morphological features were analyzed in only 64 cases, and the kinetic features in all 68 cases.
**Data are expressed as number of cases (percentage).
# Data are expressed as median (range).
Abbreviations: A, well-defined (regular); B, ill-defined (irregular o spiculated); Hom: homogeneous; Het: heterogeneous.